Abstracts tagged "secukinumab"

Abstract Number: 0908 • ACR Convergence 2021
Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
Uta Kiltz¹, Xenofon Baraliakos¹, Jan Brandt-Jrgens², Ulf Wagner³, Sebastian Lieb⁴, Christian Sieder⁵, Christian Mann⁵ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Universitätsklinikum Leipzig, Leipzig, Germany, ⁴Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammatory back pain in patients (pts) with ankylosing spondylitis (AS). However, an increased risk of side…
Abstract Number: 1738 • ACR Convergence 2021
Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Annika Boas⁶ and Hans-Peter Tony⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma GmbH, Nuernberg, Germany, ⁷Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular…
Abstract Number: 1832 • ACR Convergence 2021
Secukinumab Therapy in Biologic-naïve vs. Biologic-experienced Patients: Real-world Effectiveness, Persistence and Safety Results from the Rheumatic Diseases Portuguese Registry
Soraia Azevedo¹, Jose Tavares-Costa², Pedro Laires³, Salomé Garcia⁴, Patricia Nero⁵, Jorge Pestana⁶, Joana Martins-Martinho⁷, Ana Bento Silva⁸, Joana Rodrigues⁹, Graca Sequeira¹⁰, Emanuel Costa¹¹, Filipe Cunha Santos¹², Carolina Furtado¹³, Bernardo Santos¹⁴, Ana Raposo¹⁵, Liliana Saraiva¹⁶, Beatriz Samões¹⁷, Filipe Barcelos¹⁸, Maria José Santos⁶ and Helena Santos¹⁹, ¹Unidade Local de Saude do Alto Minho, Ponte de lima, Portugal, ²Rheumatology Department - Unidade Local de Saude do Alto Minho, Ponte de Lima, Portugal, ³Novartis Portugal / ENSP – NOVA University of Lisbon, Lisbon, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁵CUF, TELHEIRAS, Portugal, ⁶Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ⁷Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ⁸Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ⁹Rheumatology Department, ULSAM, Ponte de Lima, Portugal, ¹⁰Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ¹¹Hospital de Braga, Braga, Portugal, ¹²Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, ¹³Rheumatology Department, Hospital do Divino Espírito Santo de Ponta Delgada, Ponta Delgada, Portugal, ¹⁴Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁵Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ¹⁶Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹⁷Rheumatology Department, Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal, ¹⁸Instituto Português de Reumatologia, Lisbon, Portugal, ¹⁹Portuguese Institute of Rheumatology, Lisbon, Portugal
Background/Purpose: Secukinumab has demonstrated to be efficacious for both psoriatic arthritis (PsA) and ankylosing spondylitis (AS): PASI, ACR and ASAS magnitudes of response have generally…
Abstract Number: 934 • 2019 ACR/ARP Annual Meeting
Predictors of Survival of Secukinumab Treatment in a Multicenter Cohort of 556 Spondylarthritis
Benoit Flachaire¹, Jean-Guillaume Letarouilly ², Céline Labadie ³, Nicolas Cohen ⁴, Vincent Pradel ⁵, Jérémie Sellam ⁶, Pascal Richette ⁷, Philippe Dieudé ⁸, Pascal Claudepierre ⁹, Bruno Fautrel ¹⁰, Eric Houvenagel ¹¹, Chi Duc Nguyen ¹², Marie-Hélène Guyot ¹³, Nicolas Segaud ¹⁴, Frédéric Maury ¹⁵, Laurent Marguerie ¹⁶, Xavier Deprez ¹⁷, Jean-Hugues Salmon ¹⁸, Guy Baudens ¹⁹, Elisabeth Gervais ²⁰, Corinne Miceli-Richard ²¹, Isabelle Chary-Valckenaere ²², Pierre Lafforgue ²³, Damien Loeuille ²⁴, Christophe Richez ²⁵, René-Marc Flipo ²⁶ and Thao Pham ²³, ¹Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, ²University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, ³Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, ⁴APHM -Assistance publique des hôpitaux de Marseille, Marseille, France, ⁵APHM -Assistance publique des hôpitaux de Marseille, Marseille, Finland, ⁶Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, ⁷Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ⁸Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, ⁹Rheumatology, CHU Henri Mondor Créteil, Paris, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ¹¹Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, ¹²Rheumatology, Hospital of Béthune, Béthune, Béthune, France, ¹³Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, ¹⁴Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, ¹⁵Rheumatology, Private Practice, Beuvry, Beuvry, France, ¹⁶Rheumatology, Calot Institute, Berck, Berck-sur-Mer, ¹⁷Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, ¹⁸Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁹Rheumatology, Private Practice, Valenciennes, Valenciennes, France, ²⁰CHU de Poitiers, Rheumatology, Poitiers, France, ²¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²²Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ²³Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²⁴Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, ²⁵Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ²⁶University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France
Background/Purpose: Secukinumab (SEC) is an interleukin-17 inhibitor used to treat patients with axial spondylarthritis (axSpA) and psoriatic arthritis (PsA). Drug survival is often used as…
Abstract Number: 1494 • 2019 ACR/ARP Annual Meeting
Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
Joseph Merola¹, Shu Li ², Ming-Chun Hsu ², Chetan Karyekar ³, Susan Flavin ², Bruce Randazzo ⁴ and Laura Coates ⁵, ¹Brigham and Women's Hospital, Harvard Med School, Boston, MA, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Global Services, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Guselkumab (GUS, an antibody against IL-23) and secukinumab (SEC, an antibody against IL-17A) are both approved for the treatment of psoriasis (PsO). Up to…
Abstract Number: 1498 • 2019 ACR/ARP Annual Meeting
A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions
Tien Nguyen¹, Melvin Churchill ², Robert Levin ³, Guillermo Valenzuela ⁴, Joseph Merola ⁵, Alexis Ogdie ⁶, Ana-Maria Orbai ⁷, Jose Scher ⁸, Arthur Kavanaugh ⁹, Shital Agawane ¹⁰, Farid Kianifard ¹¹, Chauncy Rollins ¹¹ and Olivier Chambenoit ¹¹, ¹Department of Dermatology, University of California, Irvine, Irvine, CA, ²Arthritis Center of Nebraska, Lincoln, NE, ³Clinical Research of West Florida, Inc and University of South Florida, Clearwater/Tampa, FL, ⁴Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, ⁹University of California, San Diego School of Medicine, La Jolla, CA, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine…
Abstract Number: 1553 • 2019 ACR/ARP Annual Meeting
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
Philip Mease¹, Atul Deodhar ², Renato Calheiros ³, Xiangyi Meng ³, Todd Fox ⁴ and Xenofon Baraliakos ⁵, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: AS is a chronic, inflammatory disease of the axial skeleton associated with pain, stiffness, disability, and reduced quality of life (QOL).1 AS is defined…